Late-Breaking: Immune Response to COVID-19 Infection and Vaccination in Kidney Transplant Recipients – A Late-Breaking IMPACT Session happening only at the American Transplant Congress (ATC) 2021 Virtual Connect (https://atcmeeting.org/) featuring (in order of appearance):
-Dr. Paolo Cravedi, Mount Sinai
-Dr. Enver Akalin, Albert Einstein College of Medicine, Montefiore Medical Center
-Dr. Yorg Azzi, Montefiore Medical Center
About ATC:
Attend ATC 2021 Virtual Connect happening June 4-9, 2021, and get access to all the Late-Breaking COVID-19 IMPACT Sessions, groundbreaking transplantation research + scientific advancements, even more hot-topic COVID-19 content, and real-time interactivity opportunities to collaborate with global leaders in the transplantation industry.
More at: https://atcmeeting.org/
Scientific Program: https://atcmeeting.org/scientific-program-0
Registration Fees & Register: https://atcmeeting.org/registration
The American Transplant Congress is the Joint Annual Meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST). ATC provides a forum for the exchange of new scientific and clinical information relevant to solid organ and tissue transplantation and brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals, and other transplant professionals. The educational offerings provide attendees the opportunity to learn cutting-edge advances in research and exchange of ideas and practice in the field of solid organ and tissue transplantation.
Who Should Attend ATC:
The American Transplant Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel, pharmacists, and other transplant professionals who are interested in the clinical and research aspects of solid organ and tissue transplantation. The meeting will provide the most current information in the field of transplant science.
So the mortality for COVID-19 is particularly high within organ transplant recipients. And the reasons for this are not really clear. At this session, we need to update our results in kidney transplant patients which will be presented by Dr. Yorg Azzi as the first speaker of this session. And then I will talk about how our response to COVID-19 vaccination in kidney transplant patients, which is very important, because after the first dose of COVID-19 mRNA vaccination, unfortunately, the response rate is between six to 18%, which is very low compared to general population. So in my talk will go over the essays that are being used to quantify the T cell responses against the virus, the SARS-CoV-2. and how they associate with the antibody response, the immune suppression level and the clinical outcomes. I think the audience will learn about the clinical presentation but also about the antibody prevalence and dynamic and our session. And also we’ll touch base on the immunity after vaccination as well as the cellular immunity against COVID-19.